Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Pneumococcal Vaccination (PCV13+PPV23 vs PREVENAR20) in Adult Lymphoma
NCT04460235Phase 4Recruiting
- Sponsor
- CHU de Poitiers
- Start
- Sep 2021
- Primary completion
- Jun 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Prevnar 20 in pneumococcal infection, sponsored by CHU de Poitiers. Started Sep 2021; status: recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04460235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460235.